CD8A and neoplasm: MDSCs, as well as tumor cells and other types of cells in the TME, also promote immunosuppression via production of prostaglandin (PG) E2, which attenuates the anti-tumor activity of CD8+ TILs via interaction with adenylyl cyclase-coupled, PG-type E2 receptors on these cells [102].